AOD-9604 in Nova Hartz — Fat Loss Peptide Research Guide
AOD-9604 research guide for Nova Hartz. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Nova Hartz Investigators
For anyone in Nova Hartz searching for AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. The key implication for Nova Hartz researchers: sourcing AOD-9604 comes down completely to vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. What genuinely separates top AOD-9604 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. What follows is a practical research guide built specifically around AOD-9604, covering everything a Nova Hartz researcher needs to source confidently.
Understanding AOD-9604 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Nova Hartz comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Vetting AOD-9604 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. Warning signs in AOD-9604 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. Store lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order AOD-9604 — ships to Nova Hartz
COA-verified · International tracking · Research grade
All use of AOD-9604 in Nova Hartz or anywhere is research use only — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. PubMed are the primary literature resources for AOD-9604 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
